Abstract

Two-hundred and thirty-four consecutive patients with a histologic diagnosis of low malignant potential (LMP) ovarian tumors between 1972 and 1994 form the basis of this study. Six patients had a synchronous intra-abdominal or pelvic malignancy and six were considered to have areas of early stromal invasion, these patients being considered separately. The patients ages ranged from 16–93 years. The histologic type was mucinous in 53%, serous in 37%, mixed in 7%, and other in 3%. Ovarian tumors were bilateral in 15% with mucinous and 39% with serous disease. Fourteen patients had pseudomyxoma peritonei. Extra ovarian disease was found in 28 (34%) patients with serous and 15 (13%) with mucinous tumors. Five (6%) patients with serous tumors had invasive implants and four had lymph node implants. Clinically 175 patients had stage I disease, 19 had stage II and 28 stage III disease but only 88 patients were formally staged. Follow-up details were available for 173 (74%) patients, ranging from 2 months to 20 years, mean 54 months. Thirteen patients (6%) died of disease, of whom six had pseudomyxoma peritonei. Twelve patients (6%) had developed invasive malignancy of whom seven died. None of the patients with formally staged Ia or Ib disease had a recurrence. With the exception of patients with synchronous malignancy or pseudomyxoma peritonei the prognosis is good. Surgical staging offers limited prognostic information but sacrifice of fertility is not justified. Adjuvant therapy is not indicated in early stage disease and its role for patients with extra ovarian disease remains controversial.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.